The Food and Drug Administration said Thursday it is pulling back a biosimilar draft guidance that aimed to assist drugmakers comparing the analytical similarity between a reference product and a biosimilar in development.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,